ArticleCureus2025
Transformation of Lactotroph Pituitary Adenoma to Metastatic Pituitary Carcinoma: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggressive lactotrophic pituitary adenomas rarely transform into metastatic pituitary carcinoma. Moreover, the biological drivers and molecular characteristics that differentiate pituitary adenomas from pituitary carcinomas, or a reliable biomarker for metastatic potential, remain largely unknown. Therefore, long-term monitoring through clinical examinations, laboratory testing, and imaging is crucial for the early detection of such transformations. This approach can lead to aggressive multimodal treatments, including systemic therapies and radiation. Here, we present a rare case involving a 35-year-old male patient who developed an aggressive lactotrophic pituitary adenoma resistant to surgery, radiation, and medical treatments. Five years after undergoing adjuvant radiation therapy to the pituitary gland, the patient's condition progressed, resulting in distant spinal and bony metastases. He completed palliative radiation therapy for these metastases and underwent four cycles of combination immunotherapy for maintenance. Unfortunately, he was later diagnosed with immune checkpoint inhibitor-related hepatitis due to elevated liver enzymes. The case highlights the likely contribution of subtotal resection and high proliferative potential to incomplete remission, as patients without complete remission may have an increased risk of metastatic transformation. Thus, the need for early genetic testing and a prompt multimodal treatment approach is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.